Viral Vaccines Market Size Projected to Reach $81.91 billion by 2034 | 4.05%

According to Straits Research, the global viral vaccines market size was valued at $57.3 billion in 2025 and is projected to grow from $59.62 billion in 2026 to $81.91 billion by 2034, at a CAGR of 4.05% during the forecast period 2026–2034.

Viral vaccines are designed to protect the organism against viral infections by stimulating the immune system to recognize and fight against that specific virus. A harmless version of the virus is introduced into the host’s body, such as live attenuated, inactivated, or made from other viral components, such as proteins, to enhance the immune response. The immune system then recognizes the virus as foreign and produces antibodies that specifically target it. This process trains the immune system to respond more effectively if it encounters the actual virus in the future.

High prevalence rates of viral infectious diseases drive the global market

The growing global demand for viral vaccines is driven by the rising prevalence and incidence of viral diseases like COVID-19, influenza, hepatitis, and the emergence of new infections. For instance, in November 2024, the World Health Organization (WHO) reported that measles affected 10.3 million people worldwide.

In response, WHO, the Measles and Rubella Partnership and other global organizations ramped up immunization efforts, significantly lowering the death rate through vaccination. As the incidence of such diseases continues to increase, the demand for effective vaccines to curb their spread and safeguard populations grows, contributing to the continued expansion.

Expansion of mRNA vaccine technology creates tremendous opportunities

The viral vaccine market is experiencing a significant shift with the rapid advancement and expansion of mRNA vaccine technology, which offers speed, flexibility, and broad applicability across various diseases. This innovative approach is opening up new opportunities for the development of vaccines for a wide range of viral infections.

For example, in January 2023, Moderna announced that its mRNA-1345 vaccine, designed to protect against Respiratory Syncytial Virus (RSV), successfully met the primary efficacy endpoints in a Phase 3 trial involving older adults. This achievement demonstrates the potential of mRNA technology to address unmet medical needs.

As this technology evolves, it promises to revolutionize vaccine development and improve public health outcomes, creating new avenues for the global viral vaccines market.

North America remains the dominant market for the global viral vaccines market, particularly driven by the U.S. due to its advanced healthcare infrastructure, high vaccine demand, strong public healthcare initiatives, and the presence of key market players. The region’s faster-growing vaccination campaigns, such as Covid-19 and influenza, contribute significantly to the market share.

The U.S., being the home of the largest pharmaceutical companies, is developing new vaccine technologies, including m RNA vaccines and viral vector vaccines. Moreover, the Centers for Disease Control and Prevention U.S., a public health organization, plays an essential role in spreading the importance related to vaccination programs.

Key Highlights

• According to Straits Research, the global viral vaccines market size was valued at $57.3 billion in 2025 and is projected to grow from $59.62 billion in 2026 to $81.91 billion by 2034, at a CAGR of 4.05% during the forecast period 2026–2034.
• Based on types, the live attenuated vaccine segment leads the market due to its ability to trigger a strong, long-lasting immune response with fewer doses.
• Based on consumer groups, The pediatric segment is the market leader, driven by the early administration of vaccines to protect children from various infectious diseases and prevent their spread.
• Based on disease indication, The influenza disease segment holds the largest share due to the widespread impact of genetic mutations in the influenza virus, which affects large populations globally.
• Based on the route of administration, The parenteral segment dominates thanks to its faster absorption, higher efficacy, and reduced risk of contamination or degradation compared to other routes of administration.
• North America remains the dominant market for the global viral vaccines market, with 41.23% market share

Market Segments

1. By Types
   1. Live attenuated vaccines
   2. Inactivated vaccines
   3. Sub-Unit viral vaccines
2. By Consumer groups
   1. Pediatric
   2. Adults
3. By Disease Indication
   1. Cancer
   2. Influenza
   3. Human Papilloma Virus
   4. Rota Virus
   5. Poliomyelitis
   6. Hepatitis
   7. Others
4. By Route of Administration
   1. Parenteral
   2. Oral